宫颈癌新辅助化疗的疗效评估

doi:10.12280/gjfckx.20220114

摘要/Abstract

摘要：

宫颈癌是妇科最常见的恶性肿瘤,严重威胁妇女生命健康,是一个亟待解决的全球公共卫生问题。目前,宫颈癌的治疗以手术和放疗为主,化疗为辅。新辅助化疗（neoadjuvant chemotherapy,NACT）是宫颈癌患者临床常用的辅助治疗方案,具有缩小原发肿瘤体积、减少肿瘤转移等优势。然而,由于个体差异性和肿瘤异质性,不是所有患者都对化疗有应答。同时,NACT还有一定的毒性反应,如脱发、中性粒细胞减少和脏器损伤等,甚至可能导致患者死亡。目前临床最常用血清鳞状细胞癌抗原（squamous cell carcinoma antigen,SCC-Ag）和影像学检查来评估NACT的疗效,但具有一定的局限性。从影像学、病理学、分子标志物、毒性反应和生存情况5个方面综述宫颈癌NACT疗效的评估方法,为NACT的临床评估提供依据,并有助于个体化治疗方案的选择和应用。

关键词: 宫颈肿瘤, 新辅助化疗, 放化疗,辅助, 生物标记,肿瘤, 治疗结果, 个体化医疗

Abstract:

Cervical cancer is the most common malignant tumor in gynecology, which seriously threatens women′s life and health. It is a global public health problem that needs to be solved urgently. At present, the treatment of cervical cancer is mainly surgery and radiotherapy, supplemented by chemotherapy. Neoadjuvant chemotherapy (NACT) is a commonly used adjuvant therapy for patients with cervical cancer, which has the advantages of reducing the size of the primary tumor and tumor metastasis. However, due to individual variability and tumor heterogeneity, not all patients respond to chemotherapy. At the same time, NACT also has certain toxic reactions, such as hair loss, neutropenia and organ damage, and even lead to the death of patients. At present, serum squamous cell carcinoma antigen (SCC-Ag) and imaging examination are most commonly used to evaluate the efficacy of NACT, but they have some limitations. The evaluation methods of NACT for cervical cancer are reviewed from the aspects of imaging, pathology, molecular markers, toxicity and survival, to provide a basis for the clinical evaluation of NACT, and to help the selection and application of individualized treatment plans.

Key words: Uterine cervical neoplasms, Neoadjuvant chemotherapy, Chemoradiotherapy, adjuvant, Biomarkers, tumor, Treatment outcome, Individualized medicine

冯丹, 申复进. 宫颈癌新辅助化疗的疗效评估[J]. 国际妇产科学杂志, 2022, 49(5): 529-534.

FENG Dan, SHEN Fu-jin. Efficacy Evaluation of Neoadjuvant Chemotherapy for Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(5): 529-534.

参考文献 32

[1]	Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020, 8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. doi: 10.1016/S2214-109X(19)30482-6
[2]	周晖, 王冬雁, 罗铭, 等. 《FIGO 2018妇癌报告》——子宫颈癌指南解读[J]. 中国实用妇科与产科杂志, 2019, 35(1):95-103. doi: 10.19538/j.fk2019010123. doi: 10.19538/j.fk2019010123
[3]	Salvo G, Odetto D, Pareja R, et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain[J]. Int J Gynecol Cancer, 2020, 30(6):873-878. doi: 10.1136/ijgc-2020-001257. doi: 10.1136/ijgc-2020-001257 pmid: 32241876
[4]	Gadducci A, Cosio S. Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research[J]. Anticancer Res, 2020, 40(9):4819-4828. doi: 10.21873/anticanres.14485. doi: 10.21873/anticanres.14485 pmid: 32878770
[5]	Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020[J]. J Natl Compr Canc Netw, 2020, 18(6):660-666. doi: 10.6004/jnccn.2020.0027. doi: 10.6004/jnccn.2020.0027
[6]	Tian X, Wang X, Cui Z, et al. A Fifteen-Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer[J]. Adv Sci(Weinh), 2021, 8(10):2001978. doi: 10.1002/advs.202001978. doi: 10.1002/advs.202001978
[7]	白山, 王永强, 耿勇, 等. 术前新辅助化疗联合外科手术治疗非小细胞肺癌的临床效果[J]. 临床医学研究与实践, 2020, 5(29):23-25. doi: 10.19347/j.cnki.2096-1413.202029009. doi: 10.19347/j.cnki.2096-1413.202029009
[8]	Liu LT, Chen QY, Tang LQ, et al. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA[J]. J Natl Compr Canc Netw, 2019, 17(6):703-710. doi: 10.6004/jnccn.2018.7270. doi: 10.6004/jnccn.2018.7270
[9]	Dang Y, Liu Q, Long L, et al. The Effect of Neoadjuvant Chemotherapy Combined With Brachytherapy Before Radical Hysterectomy on Stage IB2 and IIA Cervical Cancer: A Retrospective Analysis[J]. Front Oncol, 2021, 11:618612. doi: 10.3389/fonc.2021.618612. doi: 10.3389/fonc.2021.618612
[10]	Marchetti C, Fagotti A, Tombolini V, et al. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis[J]. Cancer Treat Rev, 2020, 83:101945. doi: 10.1016/j.ctrv.2019.101945. doi: 10.1016/j.ctrv.2019.101945
[11]	Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247. doi: 10.1016/j.ejca.2008.10.026. doi: 10.1016/j.ejca.2008.10.026 pmid: 19097774
[12]	Perniola G, Tomao F, Graziano M, et al. The Role of 2D/3D Ultrasound to Assess the Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer[J]. Oncology, 2020, 98(11):807-813. doi: 10.1159/000505426. doi: 10.1159/000505426
[13]	Sun C, Tian X, Liu Z, et al. Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: A multicentre study[J]. EBioMedicine, 2019, 46:160-169. doi: 10.1016/j.ebiom.2019.07.049. doi: S2352-3964(19)30491-8 pmid: 31395503
[14]	Haldorsen IS, Lura N, Blaakær J, et al. What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?[J]. Curr Oncol Rep, 2019, 21(9):77. doi: 10.1007/s11912-019-0824-0. doi: 10.1007/s11912-019-0824-0 pmid: 31359169
[15]	Scandurra G, Scibilia G, Banna GL, et al. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J]. J Gynecol Oncol, 2015, 26(2):118-124. doi: 10.3802/jgo.2015.26.2.118. doi: 10.3802/jgo.2015.26.2.118 pmid: 25686397
[16]	Sutton P, Evans J, Jones R, et al. Proteomic analysis to identify biomarkers in the primary tumour that predict response to neoadjuvant chemotherapy in liver metastases[J]. Lancet, 2015, 385(Suppl 1):S95. doi: 10.1016/S0140-6736(15)60410-X. doi: 10.1016/S0140-6736(15)60410-X
[17]	Chabanon RM, Rouanne M, Lord CJ, et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities[J]. Nat Rev Cancer, 2021, 21(11):701-717. doi: 10.1038/s41568-021-00386-6. doi: 10.1038/s41568-021-00386-6 pmid: 34376827
[18]	Kubelac P, Genestie C, Auguste A, et al. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer[J]. Cancers(Basel), 2020, 12(3):707. doi: 10.3390/cancers12030707. doi: 10.3390/cancers12030707
[19]	Lin Y, Li Z, Liu M, et al. CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer[J]. Arch Gynecol Obstet, 2021, 304(2):495-501. doi: 10.1007/s00404-020-05921-8. doi: 10.1007/s00404-020-05921-8 pmid: 33392721
[20]	Zhang Y, Yan H, Li R, et al. High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin[J]. Medicine(Baltimore), 2019, 98(20):e15607. doi: 10.1097/MD.0000000000015607. doi: 10.1097/MD.0000000000015607
[21]	Zhu H, Chen A, Li S, et al. Predictive role of galectin-1 and integrin α5β1 in cisplatin-based neoadjuvant chemotherapy of bulky squamous cervical cancer[J]. Biosci Rep, 2017, 37(5):BSR20170958. doi: 10.1042/BSR20170958. doi: 10.1042/BSR20170958
[22]	Kfouri CFDA, Lombardi W, Romania MCFN, et al. Prognostic factors for response to chemotherapy in advanced tumors of the uterine cervix: the role of neoangiogenesis[J]. Rev Col Bras Cir, 2019,46(1): e 2077. doi: 10.1590/0100-6991e-20192077. doi: 10.1590/0100-6991e-20192077
[23]	Heeren AM, van Luijk IF, Lakeman J, et al. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer[J]. Cancer Immunol Immunother, 2019, 68(11):1759-1767. doi: 10.1007/s00262-019-02412-x. doi: 10.1007/s00262-019-02412-x pmid: 31616965
[24]	Liang Y, Lü W, Zhang X, et al. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer[J]. Diagn Pathol, 2018, 13(1):93. doi: 10.1186/s13000-018-0770-4. doi: 10.1186/s13000-018-0770-4 pmid: 30474571
[25]	D′Alessandris N, Palaia I, Pernazza A, et al. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer[J]. Virchows Arch, 2021, 478(3):517-525. doi: 10.1007/s00428-020-02922-5. doi: 10.1007/s00428-020-02922-5
[26]	Liang Y, Yu M, Zhou C, et al. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy[J]. Diagn Pathol, 2020, 15(1):67. doi: 10.1186/s13000-020-00977-1. doi: 10.1186/s13000-020-00977-1 pmid: 32493336
[27]	Ferrall L, Lin KY, Roden RBS, et al. Cervical Cancer Immunotherapy: Facts and Hopes[J]. Clin Cancer Res, 2021, 27(18):4953-4973. doi: 10.1158/1078-0432.CCR-20-2833. doi: 10.1158/1078-0432.CCR-20-2833 pmid: 33888488
[28]	Chen P, Jiao L, Ren F, et al. Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma[J]. BMC Cancer, 2020, 20(1):423. doi: 10.1186/s12885-020-06934-x. doi: 10.1186/s12885-020-06934-x pmid: 32410650
[29]	Yoo JG, Kim SI, Yeo SG, et al. Usefulness of Short-Term Imaging and Squamous Cell Carcinoma Antigen to Early Predict Response to Concurrent Chemoradiotherapy in Patients With Cervical Cancer[J]. Cancer Control, 2022, 29:10732748221074530. doi: 10.1177/10732748221074530. doi: 10.1177/10732748221074530
[30]	Liang WF, Li H, Wu JY, et al. Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram[J]. Front Oncol, 2020, 10:560888. doi: 10.3389/fonc.2020.560888. doi: 10.3389/fonc.2020.560888
[31]	Tian X, Yang F, Li F, et al. A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study[J]. Cancer Manag Res, 2021, 13:8307-8316. doi: 10.2147/CMAR.S328309. doi: 10.2147/CMAR.S328309 pmid: 34764693
[32]	Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage ⅠB2, ⅡA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial[J]. J Clin Oncol, 2018, 36(16):1548-1555. doi: 10.1200/JCO.2017.75.9985. doi: 10.1200/JCO.2017.75.9985